Market Cap 9.10M
Revenue (ttm) 16.02M
Net Income (ttm) 3.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 22.41%
Debt to Equity Ratio 0.00
Volume 94,133
Avg Vol 565,798
Day's Range N/A - N/A
Shares Out 3.04M
Stochastic %K 8%
Beta -0.66
Analysts Strong Sell
Price Target $11.00

Company Profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 224 9600
Address:
332 Encinitas Boulevard, Suite 102, Encinitas, United States
Jake140
Jake140 Jul. 24 at 11:01 AM
$KPRX Patience, patience. Takes time...
0 · Reply
astonm
astonm Jul. 23 at 10:53 AM
0 · Reply
Jake140
Jake140 Jul. 23 at 8:39 AM
0 · Reply
biolevity
biolevity Jul. 22 at 4:17 PM
$KPRX another name to watch. Low float, doesn't need cash, but clinical milestones are in 2026. Still, wouldn't take much to make it pop
0 · Reply
KioraIR
KioraIR Jul. 22 at 1:19 PM
$KPRX Today we were issued a patent (USPTO # 12,364,680), which extends protection for KIO-104 in treating ocular inflammation, uveitis, AMD, and post-surgical complications. More specifically, the patent strengthens IP around dosing, formulation, and methods, extending exclusivity to 2043. KIO-104 is a potent small molecule in development for inflammatory retinal diseases with the goal of providing an alternative to steroids or systemic anti-inflammatory drugs. A multicenter Phase 2 clinical trial, the KLARITY study, is currently screening patients to investigate KIO-104 at two dose levels across several forms of inflammatory retinal disease. Read more > https://ir.kiorapharma.com/news-events/news-releases/detail/235/kiora-pharmaceuticals-granted-u-s-patent-expanding-protection-for-kio-104-in-the-treatment-of-ocular-disease
0 · Reply
DARKP00L
DARKP00L Jul. 22 at 1:17 PM
$KPRX 09:09 on Jul. 22 2025 Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection For KIO-104 In The Treatment of Ocular Disease #tradeideas
0 · Reply
enzomassimi
enzomassimi Jul. 22 at 1:13 PM
0 · Reply
newsfile_corp
newsfile_corp Jul. 22 at 12:56 PM
https://nfne.ws/259471 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Patent #NASDAQ #Investing
0 · Reply
Jake140
Jake140 Jul. 18 at 4:54 PM
$KPRX Nice!
0 · Reply
Jake140
Jake140 Jul. 18 at 9:37 AM
$KPRX Moving up!
0 · Reply
Latest News on KPRX
Bonds still bouncing along

Sep 9, 2024, 4:55 PM EDT - 11 months ago

Bonds still bouncing along

CPLS EYEG HYFI JPST TLT USHY YEAR


AllianceBernstein Launches Five New Active ETFs

Dec 13, 2023, 7:30 AM EST - 1 year ago

AllianceBernstein Launches Five New Active ETFs

AB BUFC CPLS EYEG TAFL TAFM


Jake140
Jake140 Jul. 24 at 11:01 AM
$KPRX Patience, patience. Takes time...
0 · Reply
astonm
astonm Jul. 23 at 10:53 AM
0 · Reply
Jake140
Jake140 Jul. 23 at 8:39 AM
0 · Reply
biolevity
biolevity Jul. 22 at 4:17 PM
$KPRX another name to watch. Low float, doesn't need cash, but clinical milestones are in 2026. Still, wouldn't take much to make it pop
0 · Reply
KioraIR
KioraIR Jul. 22 at 1:19 PM
$KPRX Today we were issued a patent (USPTO # 12,364,680), which extends protection for KIO-104 in treating ocular inflammation, uveitis, AMD, and post-surgical complications. More specifically, the patent strengthens IP around dosing, formulation, and methods, extending exclusivity to 2043. KIO-104 is a potent small molecule in development for inflammatory retinal diseases with the goal of providing an alternative to steroids or systemic anti-inflammatory drugs. A multicenter Phase 2 clinical trial, the KLARITY study, is currently screening patients to investigate KIO-104 at two dose levels across several forms of inflammatory retinal disease. Read more > https://ir.kiorapharma.com/news-events/news-releases/detail/235/kiora-pharmaceuticals-granted-u-s-patent-expanding-protection-for-kio-104-in-the-treatment-of-ocular-disease
0 · Reply
DARKP00L
DARKP00L Jul. 22 at 1:17 PM
$KPRX 09:09 on Jul. 22 2025 Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection For KIO-104 In The Treatment of Ocular Disease #tradeideas
0 · Reply
enzomassimi
enzomassimi Jul. 22 at 1:13 PM
0 · Reply
newsfile_corp
newsfile_corp Jul. 22 at 12:56 PM
https://nfne.ws/259471 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Patent #NASDAQ #Investing
0 · Reply
Jake140
Jake140 Jul. 18 at 4:54 PM
$KPRX Nice!
0 · Reply
Jake140
Jake140 Jul. 18 at 9:37 AM
$KPRX Moving up!
0 · Reply
Jake140
Jake140 Jul. 17 at 11:02 AM
$KPRX Morning All! Onward and upward!
0 · Reply
Flowdollas
Flowdollas Jul. 16 at 6:16 PM
$KPRX Lets go! Been waiting 2 years.
0 · Reply
Jake140
Jake140 Jul. 9 at 5:58 PM
$KPRX Yaaay...finally some movement here!
0 · Reply
Jake140
Jake140 Jul. 7 at 10:42 AM
$KPRX Morning!
0 · Reply
Jake140
Jake140 Jun. 26 at 11:25 AM
$KPRX Holding!
0 · Reply
Turki55700
Turki55700 Jun. 25 at 3:13 PM
$KPRX What is this weird stock
0 · Reply
romarcin23
romarcin23 Jun. 20 at 8:27 PM
$KPRX Why is there suddenly volume on no news?
0 · Reply
KhalidsCapital
KhalidsCapital Jun. 20 at 12:06 AM
GLMD Tiny float. No debt. No dilution. $12+ book. Under cash. Real biotech catalysts incoming. These setups don’t stay quiet for long. $SLS $IQAI $ENSC $KPRX
1 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 17 at 10:55 PM
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 17 at 11:09 AM
$BINI $BANL $HOLO and maybe $KPRX if it can get some volume
1 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 17 at 12:53 AM
$BINI $KPRX sentiment at 42
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 17 at 12:18 AM
$BINI $SCNI $BANL $KPRX ready to sploosh me thinks
0 · Reply